Complexity of neutralizing antibodies against multiple dengue virus serotypes after heterotypic immunization and secondary infection revealed by in-depth analysis of cross-reactive antibodies

Journal of Virology

Volumn 89, Issue 14, 2015, Pages 7348-7362

  Tsai, Wen Yang ^a   Durbin, Anna ^b   Tsai, Jih Jin ^c,d   Hsieh, Szu Chia ^a   Whitehead, Stephen ^e   Wang, Wei Kung ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; DENGUE VACCINE; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CASE REPORT; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; HETEROTYPIC IMMUNIZATION; HUMAN; IMMUNIZATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY INFECTION; VIRUS NEUTRALIZATION; ANTIBODY AFFINITY; BLOOD; CROSS REACTION; DENGUE VIRUS; HETEROLOGOUS IMMUNITY; IMMUNOLOGY; MIXED INFECTION; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; SEROTYPE; VIROLOGY;

DENGUE VIRUS;

ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; COINFECTION; CROSS REACTIONS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; IMMUNITY, HETEROLOGOUS; IMMUNOGLOBULIN G; NEUTRALIZATION TESTS; SEROGROUP; VACCINES, ATTENUATED;

EID: 84931081889     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00273-15     Document Type: Article

References (72)

1. Simmons CP, Farrar JJ, Nguyen V, Wills B. 2012. Dengue. N Engl J Med 366:1423-1432. http://dx.doi.org/10.1056/NEJMra1110265.
2. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http://dx.doi.org/10.1038/nature12060.
3. World Health Organization. 2009. Dengue hemorrhagic fever: diagnosis, treatment, prevention and control, 3rd ed. WHO, Geneva, Switzerland.
4. Murphy BR, Whitehead SS. 2011. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29:587-619. http://dx.doi.org/10.1146/annurev-immunol-031210-101315.
5. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYDtetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736(12)61428-7.
6. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, CYD14 Study Group. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358-1365. http://dx.doi.org/10.1016/S0140-6736(14)61060-6.
7. Villar L, Dayan GH, Arredondo-García JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramírez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Montoya MC, Supelano MC, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F. CYD15 Study Group. 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113-123. http://dx.doi.org/10.1056/NEJMoa1411037.
8. Anonymous. 2012. Defeating dengue: a challenge for a vaccine. Nat Med 18:1622-1623. http://dx.doi.org/10.1038/nm.2997.
9. Wilder-Smith A. 2014. Dengue vaccines: dawning at last? Lancet 384: 1327-1329. http://dx.doi.org/10.1016/S0140-6736(14)61142-9.
10. Halstead SB. 2013. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 31:4501-4507. http://dx.doi.org/10.1016/j.vaccine.2013.06.079.
11. Lindenbach BD, Murray CL, Thiel HJ, Rice CM. 2013. Flaviviridae, p 712-747. In Knipe DM, Howley PM (ed), Fields virology, 6th ed. Lippincott William & Wilkins, Philadelphia, PA.
12. Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-319. http://dx.doi.org/10.1038/nature02165.
13. Crill WD, Roehrig JT. 2001. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75:7769-7773. http://dx.doi.org/10.1128/JVI.75.16.7769-7773.2001.
14. Liao M, Sánchez-San Martín C, Zheng A, Kielian M. 2010. In vitro reconstitution reveals key intermediate states of trimer formation by the dengue virus membrane fusion protein. J Virol 84:5730-5740. http://dx.doi.org/10.1128/JVI.00170-10.
15. Stiasny K, Kiermayr S, Holzmann H, Heinz FX. 2006. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80:9557-9568. http://dx.doi.org/10.1128/JVI.00080-06.
16. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EG, Brandt WE. 1989. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70:37-43. http://dx.doi.org/10.1099/0022-1317-70-1-37.
17. Crill WD, Hughes HR, Delorey MJ, Chang GJ. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One 4:e4991. http://dx.doi.org/10.1371/journal.pone.0004991.
18. Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349-360. http://dx.doi.org/10.1016/j.virol.2007.05.042.
19. Sukupolvi-Petty S, Austin K, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Type and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81:12816-12826. http://dx.doi.org/10.1128/JVI.00432-07.
20. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin K, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog 6:e1000823. http://dx.doi.org/10.1371/journal.ppat.1000823.
21. Lin HE, Tsai WY, Liu IJ, Li PC, Liao MY, Tsai JJ, Wu YC, Lai CY, Lu CH, Huang JH, Chang GJ, Wu HC, Wang WK. 2012. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high-throughput assay. PLoS Negl Trop Dis 6:e1447. http://dx.doi.org/10.1371/journal.pntd.0001447.
22. Costin JM, Zaitseva E, Kahle KM, Nicholson CO, Rowe DK, Graham AS, Bazzone LE, Hogancamp G, Figueroa Sierra M, Fong RH, Yang ST, Lin L, Robinson JE, Doranz BJ, Chernomordik LV, Michael SF, Schieffelin JS, Isern S. 2013. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol 87:52-66. http://dx.doi.org/10.1128/JVI.02273-12.
23. Tsai WY, Lai CY, Wu YC, Lin HE, Edwards E, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK. 2013. High avidity and potent neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection. J Virol 87:12562-12575. http://dx.doi.org/10.1128/JVI.00871-13.
24. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE, Jr. 2013. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio 4(6):e00873-13. http://dx.doi.org/10.1128/mBio.00873-13.
25. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey RA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283. http://dx.doi.org/10.1016/j.chom.2010.08.007.
26. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brian J, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis 5:e1188. http://dx.doi.org/10.1371/journal.pntd.0001188.
27. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, Jr de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 109:7439-7444. http://dx.doi.org/10.1073/pnas.1200566109.
28. Teoh EP, Kukkaro PP, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko VA, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, MacAry PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med 4:139ra83. http://dx.doi.org/10.1126/scitranslmed.3003888.
29. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE, Jr. 2014. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. J Virol 88: 12233-12241. http://dx.doi.org/10.1128/JVI.00247-14.
30. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinsky A, Jumnainsong A, Edwards C, Quyen NT, Duangchinda T, Grimes JM, Tsai WY, Lai CY, Wang WK, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. 2015. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170-177. http://dx.doi.org/10.1038/ni.3058.
31. Sabin AB. 1952. Research on dengue during World War II. Am J Trop Med Hyg 1:30-50.
32. Innis BL. 1997. Antibody responses to dengue virus infection, p 221-244. In Gubler DJ, Kuno G (ed), Dengue and dengue hemorrhagic fever. CAB International, Cambridge, MA.
33. Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S, Morier L, Alvarez A, Gould EA, Kouri G, Halstead SB. 2007. Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 13:282-286. http://dx.doi.org/10.3201/eid1302.060539.
34. Imrie A, Meeks J, Gurary A, Sukhbaatar M, Truong TT, Cropp CB, Effler P. 2007. Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol 20:672-675. http://dx.doi.org/10.1089/vim.2007.0050.
35. Halstead SB. 2003. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60:421-467. http://dx.doi.org/10.1016/S0065-3527(03)60011-4.
36. Gibbons RV, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, Endy TP, Mammen MP, Jr, Srikiatkhachorn A. 2007. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg 77:910-913.
37. Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, Kochel TJ, Scott TW, Stoddard ST. 2013. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 208: 1026-1033. http://dx.doi.org/10.1093/infdis/jit273.
38. Halstead SB, Shotwell H, Casals J. 1973. Studies on the pathogenesis of dengue infection in monkeys. I. Clinical laboratory responses to primary infection. J Infect Dis 128:7-14.
39. Scherer WF, Breakenridge FA, Dickerman RW. 1972. Cross-protection studies and search for subclinical disease in new world monkeys infected sequentially with different immunologic types of dengue viruses. Am J Epidemiol 95:67-79.
40. Price WH. 1968. Sequential immunization as a vaccination procedure against dengue viruses. Am J Epidemiol 88:392-397.
41. Whitehead RH, Chaicumpa V, Olson LC, Russell PK. 1970. Sequential dengue virus infections in the white-handed gibbon (Hylobates lar). Am J Trop Med Hyg 19:94-102.
42. Lai CY, Tsai WY, Lin SR, Kao CL, Hu SP, King CC, Wu HC, Wang WK. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82:6631-8843. http://dx.doi.org/10.1128/JVI.00316-08.
43. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103-113. http://dx.doi.org/10.1016/j.virol.2009.06.037.
44. Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, Wang WK. 2013. Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis 7:e2451. http://dx.doi.org/10.1371/journal.pntd.0002451.
45. Durbin AP, Schmidt A, Elwood D, Wanionek KA, Lovchik J, Thumar B, Murphy BR, Whitehead SS. 2011. Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J Infect Dis 203: 327-334. http://dx.doi.org/10.1093/infdis/jiq059.
46. Chu PY, Ke GM, Chen PC, Liu LT, Tsai YC, Tsai JJ. 2013. Spatiotemporal dynamics and epistatic interaction sites in dengue virus type 1: a comprehensive sequence-based analysis. PLoS One 8:e74165. http://dx.doi.org/10.1371/journal.pone.0074165.
47. McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE, Jr, Murphy BR, Whitehead SS. 2008. Phase I clinical evaluation of rDEN4Δ30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg 79:678-684.
48. Verma S, Lo Y, Chapagain M, Lum S, Kumar M, Gurjav U, Luo H, Nakatsuka A, Nerurkar VR. 2009. West Nile virus infection modulates human brain microvascular endothelial cells tight junction proteins and cell adhesion molecules: transmigration across the in vitro blood-brain barrier. Virology 385:425-433. http://dx.doi.org/10.1016/j.virol.2008.11.047.
49. Zompi S, Montoya M, Pohl O, Balmaseda A, Harris E. 2012. Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. PLoS Negl Trop Dis 6:e1568. http://dx.doi.org/10.1371/journal.pntd.0001568.
50. de Souza VA, Tateno AF, Oliveira RR, Domingues RB, Araújo ES, Kuster GW, Pannuti CS. 2007. Sensitivity and specificity of three ELISAbased assays for discriminating primary from secondary acute dengue virus infection. J Clin Virol 39:230-233. http://dx.doi.org/10.1016/j.jcv.2007.04.005.
51. Matheus S, Deparis X, Labeau B, Lelarge J, Morvan J, Dussart P. 2005. Discrimination between primary and secondary dengue virus infection by an immunoglobulin G avidity test using a single acute-phase serum sample. J Clin Microbiol 43:2793-2797. http://dx.doi.org/10.1128/JCM.43.6.2793-2797.2005.
52. VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC. 2013. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog 9:e1003761. http://dx.doi.org/10.1371/journal.ppat.1003761.
53. Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE, Jr, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS. 2014. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci USA 111:1939-1944. http://dx.doi.org/10.1073/pnas.1317350111.
54. Mathew A, West K, Kalayanarooj S, Gibbons RV, Srikiatkhachorn A, Green S, Libraty D, Jaiswal S, Rothman AL. 2011. B-cell responses during primary and secondary dengue virus infections in humans. J Infect Dis 204:1514-1522. http://dx.doi.org/10.1093/infdis/jir607.
55. Wrammert J, Onlamoon N, Akondy RS, Perng GC, Polsrila K, Chandele A, Kwissa M, Pulendran B, Wilson PC, Wittawatmongkol O, Yoksan S, Angkasekwinai N, Pattanapanyasat K, Chokephaibulkit K, Ahmed R. 2012. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol 86:2911-2918. http://dx.doi.org/10.1128/JVI.06075-11.
56. Xu M, Hadinoto V, Appanna R, Joensson K, Toh YX, Balakrishnan T, Ong SH, Warter L, Leo YS, Wang CI, Fink K. 2012. Plasmablasts generated during repeated dengue infection are virus glycoproteinspecific and bind to multiple virus serotypes. J Immunol 189:5877-5885. http://dx.doi.org/10.4049/jimmunol.1201688.
57. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE, Jr. 2012. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. J Virol 86:2665-2675. http://dx.doi.org/10.1128/JVI.06335-11.
58. Ferlenghi I, Clarke M, Ruttan T, Allison SL, Schalich J, Heinz FX, Harrison SC, Rey FA, Fuller SD. 2001. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell 7:593-602. http://dx.doi.org/10.1016/S1097-2765(01)00206-4.
59. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, Girard-Blanc C, Petres S, Shepard WE, Desprès P, Arenzana-Seisdedos F, Dussart P, Mongkolsapaya J, Screaton GR, Rey FA. 2015. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520:109-113. http://dx.doi.org/10.1038/nature14130.
60. Morse SS. 1990. Critical factors in an enzyme immunoassay (ELISA) for antibodies to mouse thymic virus (MTLV). Lab Anim 24:313-320. http://dx.doi.org/10.1258/002367790780865985.
61. Namekar M, Kumar M, O'Connell M, Nerurkar VR. 2012. Effect of serum heat-inactivation and dilution on detection of anti-WNV antibodies in mice by West Nile virus E-protein microsphere immunoassay. PLoS One 7:e45851. http://dx.doi.org/10.1371/journal.pone.0045851.
62. Halstead SB, Rojanasuphot S, Sangkawibha N. 1983. Original antigenic sin in dengue. Am J Trop Med Hyg 32:154-156.
63. Kuno G, Gubler DJ, Oliver A. 1993. Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections. Trans R Soc Trop Med Hyg 87:103-105. http://dx.doi.org/10.1016/0035-9203(93)90444-U.
64. Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E. 2013. Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans. PLoS Negl Trop Dis 7:e2274. http://dx.doi.org/10.1371/journal.pntd.0002274.
65. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 38:411-419.
66. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, Jarman RG, Yoon IK, Gibbons RV, Brion JD, Capeding RZ. 2009. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 6:e1000171. http://dx.doi.org/10.1371/journal.pmed.1000171.
67. Parameswaran P, Liu Y, Roskin KM, Jackson KK, Dixit VP, Lee JY, Artiles KL, Zompi S, Vargas MJ, Simen BB, Hanczaruk B, McGowan KR, Tariq MA, Pourmand N, Koller D, Balmaseda A, Boyd SD, Harris E, Fire AZ. 2013. Convergent antibody signatures in human dengue. Cell Host Microbe 13:691-700. http://dx.doi.org/10.1016/j.chom.2013.05.008.
68. + T cells. Proc Natl Acad Sci USA 110:E2046-53. http://dx.doi.org/10.1073/pnas.1305227110.
69. Gotuzzo E, Yactayo S, Córdova E. 2013. Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg 89:434-444. http://dx.doi.org/10.4269/ajtmh.13-0264.
70. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. 2005. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 23:5205-5211. http://dx.doi.org/10.1016/j.vaccine.2005.07.002.
71. Roehrig JT, Hombach J, Barrett AD. 2008. Guidelines for plaquereduction neutralization testing of human antibodies to dengue viruses. Viral Immunol 21:123-132. http://dx.doi.org/10.1089/vim.2008.0007.
72. Dayan GH, Thakur M, Boaz M, Johnson C. 2013. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine 31:5047-5054. http://dx.doi.org/10.1016/j.vaccine.2013.08.088.